News

The American Journal of Managed Care1y
EMERALD-1: Durvalumab and Bevacizumab Plus TACE Improves PFS in Patients With Unresectable HCC
Transcatheter arterial chemoembolization (TACE), has been the current standard of care for 20 years for patients with uHCC who can receive embolization. The process involves targeting tumors by ...
ascopubs.org13y
Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC ...
Background: The global SPACE trial was conducted to evaluate the efficacy and safety of S in combination with TACE with DEBDOX in patients (pts) with intermediate-stage HCC (BCLC B). Methods: Pts were ...
Global Times3mon
CHANCE 2005/CARES-005 Study Shows PFS Benefit with Combination of Camrelizumab/Rivoceranib and TACE in Unresectable hepatocellular carcinoma (HCC)
TACE has been established as the standard treatment for intermediate HCC, but the long-term survival is limited. Although immunotherapy-based treatments have led to success in advanced HCC ...
ascopubs.org3y
LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
The LEAP-012 study (NCT04246177) is investigating lenvatinib plus pembrolizumab in combination with TACE versus placebo plus TACE in patients with intermediate-stage HCC. Methods: LEAP-012 is a ...